IMMELA (Link Medical Products Pty Ltd T/A Link Pharmaceuticals)
Product name
IMMELA
Date registered
Evaluation commenced
Decision date
Approval time
210 (255 working days)
Active ingredients
melatonin
Registration type
EOI
Indication
Adult
Short-term treatment of jet lag in adults aged 18 and over.
Paediatric
Sleep disorders in children and adolescents aged 6 to 18 with neurodevelopmental disorders including autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD), where sleep hygiene measures have been insufficient.